Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism.

Cardiol Ther · 2016 · PMC4906085 · PMID 26935434

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

a favorable trendp = 0.08so close (0.05 < p ≤ 0.1)

an unfavorable trendp = 0.10so close (0.05 < p ≤ 0.1)

The intention-to-treat analysis demonstrated a favorable trend with high-dose edoxaban (1.57% high-dose edoxaban versus 1.8% warfarin; p = 0.08) and an unfavorable trend with low-dose edoxaban (2.04% low-dose edoxaban; p = 0.10).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.